The Scandinavian hemodilution study in acute ischemic stroke used the neurological scale presented here in assessing prognosis and long-term outcome. The purpose of the present study was to test its interobserver reliability. The scale consists of two parts: one for assessing the acute prognosis and one for assessing the neurological deficit acutely and at follow-up. The items rated are: consciousness, gaze palsy, Iimb weakness, dysphasia, orientation, facial palsy and gait. Fifty acute stroke patients were rated by 2 doctors each. The agreement rates were corrected for chance (kappa statistics). Interobserver agreement was good to excellent with weighted kappa values ranging from 0.688 to 0.912. Patients who died within 6 weeks had a lower prognostic score than the survivors. The long-term scores of 2 observers were highly correlated (R = 0.954). The scale provides a reliable instrument for stratification of stroke patients and for evaluation of long-term outcome.

Keywords:
Stroke rating scales, Therapeutic trials in stroke, Hemodilution, Kappa statistics
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.